2022
Clinical, functional and prognostic implications of severe atrial dilation in secondary mitral regurgitation
Layoun H, Mentias A, Akintoye E, Matta M, Kanaan C, Daou R, Ramchand J, Burns D, Gillinov A, Bhattacharya S, Puri R, Collier P, Griffin B, Kapadia S, Harb S. Clinical, functional and prognostic implications of severe atrial dilation in secondary mitral regurgitation. Open Heart 2022, 9: e001996. PMID: 35383126, PMCID: PMC8984044, DOI: 10.1136/openhrt-2022-001996.Peer-Reviewed Original ResearchConceptsSecondary mitral regurgitationAtrial dilationMitral regurgitationPrognostic implicationsSevere left atrial dilationSevere secondary mitral regurgitationLA reservoir strainLeft atrial dilationLeft ventricle dysfunctionPoor prognostic indicatorMV interventionVentricle dysfunctionMore diabetesAdult patientsTransthoracic echocardiographyEjection fractionIndependent predictorsAtrial fibrillationReservoir strainWorse prognosisPrognostic indicatorMR severityBetter outcomesFunctional alterationsPatients
2021
Differential inflammatory responses of the native left and right ventricle associated with donor heart preservation
Lei I, Huang W, Ward PA, Pober JS, Tellides G, Ailawadi G, Pagani FD, Landstrom AP, Wang Z, Mortensen RM, Cascalho M, Platt J, Chen Y, Lam HYK, Tang PC. Differential inflammatory responses of the native left and right ventricle associated with donor heart preservation. Physiological Reports 2021, 9: e15004. PMID: 34435466, PMCID: PMC8387788, DOI: 10.14814/phy2.15004.Peer-Reviewed Original ResearchConceptsRight ventricleCold ischemiaIL-10Inflammatory responseIL-6 protein levelsCold ischemic preservationEx vivo ischemiaLeft ventricle dysfunctionCold ischemic timeDonor heart preservationInflammatory cytokine expressionCell deathDifferential inflammatory responseTumor necrosis factorComparable inflammatory responsesHuman donor heartsCaspase-3 expressionIschemic preservationVentricle dysfunctionInflammasome expressionIschemic timeRNA sequencingContractile dysfunctionDonor heartsWarm perfusion
2017
Stem Cell Therapy for Congenital Heart Disease
Tsilimigras DI, Oikonomou EK, Moris D, Schizas D, Economopoulos KP, Mylonas KS. Stem Cell Therapy for Congenital Heart Disease. Circulation 2017, 136: 2373-2385. PMID: 29229621, DOI: 10.1161/circulationaha.117.029607.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCongenital heart diseaseCell therapyHeart diseaseClinical trialsGold standard treatment modalityHypoplastic left heart syndromePulmonary artery hypertensionRight ventricle dysfunctionStandard treatment modalityAlternative treatment optionLarge clinical studiesStem cell deliveryQuality of lifeCell-based therapeutic strategiesArtery hypertensionStem cell-based therapeutic strategiesVentricle dysfunctionSurgical palliationVolume overloadHeart syndromeSafety profileCell-seeded graftsCochrane LibraryTreatment optionsTreatment modalities
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply